
IceCure Medical Ltd. (NASDAQ:ICCM – Free Report) – Equities research analysts at Brookline Capital Markets issued their Q1 2027 earnings estimates for shares of IceCure Medical in a research note issued on Wednesday, November 18th. Brookline Capital Markets analyst K. Dolliver forecasts that the company will post earnings per share of ($0.75) for the quarter. The consensus estimate for IceCure Medical’s current full-year earnings is ($4.61) per share. Brookline Capital Markets also issued estimates for IceCure Medical’s Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.62) EPS and FY2029 earnings at $0.30 EPS.
A number of other research firms have also weighed in on ICCM. Zacks Research upgraded shares of IceCure Medical from a “strong sell” rating to a “hold” rating in a report on Monday, October 12th. Wall Street Zen cut IceCure Medical from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, IceCure Medical presently has an average rating of “Hold” and a consensus target price of $30.00.
Read Our Latest Report on IceCure Medical
IceCure Medical Stock Performance
ICCM stock opened at $1.00 on Friday. The firm’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $6.74. IceCure Medical has a 12-month low of $0.65 and a 12-month high of $22.20.
About IceCure Medical
IceCure Medical Ltd. is an Israel-based medical technology company that develops and commercializes minimally invasive cryoablation systems. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, offering a percutaneous approach to treating tumors. The company’s ProSense system is designed for image-guided cryoablation and is used in procedures involving breast, kidney, lung, bone and other tumors. IceCure also offers the IceSense3 system for treating benign breast fibroadenomas.
Featured Articles
- Five stocks we like better than IceCure Medical
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
